Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD. | Cancer Sci | 2025 | 39805702 | PubTator, text mining | PubMed |
| Enterolactone combined with m6A Reader IGF2BP3 inhibits malignant angiogenesis and disease progression in ovarian cancer. | Phytomedicine | 2025 | 39765033 | PubTator, text mining | PubMed |
| LIN28A-dependent lncRNA NEAT1 aggravates sepsis-induced acute respiratory distress syndrome through destabilizing ACE2 mRNA by RNA methylation. | J Transl Med | 2025 | 39762837 | PubTator, text mining | PubMed |
| The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma. | Ann Hepatol | 2025 | 39756795 | PubTator, text mining | PubMed |
| WTAP/IGF2BP3 Mediated m6A Modification of SOD2 mRNA Aggravates the Tumourigenesis of Colorectal Cancer. | J Biochem Mol Toxicol | 2025 | 39749662 | PubTator, text mining | PubMed |
| Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. | Nat Commun | 2025 | 39747079 | PubTator, text mining | PubMed |
| Exosome-Shuttled METTL14 From AML-Derived Mesenchymal Stem Cells Promotes the Proliferation and Radioresistance in AML Cells by Stabilizing ROCK1 Expression via an m6A-IGF2BP3-Dependent Mechanism. | Drug Dev Res | 2025 | 39690960 | PubTator, text mining | PubMed |
| m6A-modified circCREBBP enhances radiosensitivity of esophageal squamous cell carcinoma by reducing the stability of MYC through interaction with IGF2BP3. | Int J Biol Macromol | 2025 | 39653202 | PubTator, text mining | PubMed |
| FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner. | Mol Cell Biochem | 2025 | 39630361 | PubTator, text mining | PubMed |
| ALKBH5 controlled autophagy of peripheral blood mononuclear cells by regulating NRG1 mRNA stability in ankylosing spondylitis. | Int Immunopharmacol | 2025 | 39580857 | PubTator, text mining | PubMed |
| Sci-ModoM: a quantitative database of transcriptome-wide high-throughput RNA modification sites. | Nucleic Acids Res | 2025 | 39498498 | PubTator, text mining | PubMed |
| ALKBH5-Mediated m6A Modification of XBP1 Facilitates NSCLC Progression Through the IL-6-JAK-STAT3 Pathway. | Mol Carcinog | 2025 | 39387829 | PubTator, text mining | PubMed |
| IGF2BP3 suppresses ferroptosis in lung adenocarcinoma by m6A-dependent regulation of TFAP2A to transcriptionally activate SLC7A11/GPX4. | Mol Cell Biochem | 2025 | 39026029 | PubTator, text mining | PubMed |
| RETRACTED: Exploring the tumor microenvironment: Chemokine-related genes and immunotherapy/chemotherapy response in clear-cell renal cell carcinoma. | Environ Toxicol | 2025 | 38488671 | PubTator, text mining | PubMed |
| Interplay of circular RNAs in gastric cancer - a systematic review. | Front Syst Biol | 2024 | 40809111 | PubTator, text mining | PubMed |
| Construction and clinical application of a risk model based on N6-methyladenosine regulators for colorectal cancer. | PeerJ | 2024 | 39717046 | PubTator, text mining | PubMed |
| The 12th international workshop on the CCN family of genes in pictures. | J Cell Commun Signal | 2024 | 39691871 | PubTator, text mining | PubMed |
| N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer. | Hum Cell | 2024 | 39680264 | PubTator, text mining | PubMed |
| The miR-6240 target gene Igf2bp3 promotes myoblast fusion by enhancing myomaker mRNA stability. | Cell Mol Biol Lett | 2024 | 39639214 | PubTator, text mining | PubMed |
| Downregulation of miR-25-3p and Its Impact on PTAFR and IGF2BP3 Expression in Type 2 Diabetes Mellitus: Implications for Biomarker Discovery and Disease Pathogenesis. | J Clin Med Res | 2024 | 39635336 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=15